Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News C4 Therapeutics Inc CCCC

Healthcare Biotechnology
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology... see more

Recent & Breaking News (NDAQ:CCCC)

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

GlobeNewswire 11 days ago

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

GlobeNewswire March 25, 2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 9, 2026

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

GlobeNewswire February 26, 2026

C4 Therapeutics to Participate in Upcoming March Conferences

GlobeNewswire February 23, 2026

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

GlobeNewswire February 23, 2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 9, 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

GlobeNewswire February 4, 2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 26, 2026

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

GlobeNewswire January 14, 2026

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

GlobeNewswire November 25, 2025

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire November 6, 2025

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

GlobeNewswire October 16, 2025

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

GlobeNewswire October 1, 2025

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

GlobeNewswire September 20, 2025

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

GlobeNewswire September 4, 2025

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

GlobeNewswire September 3, 2025

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire August 7, 2025

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire May 7, 2025

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

GlobeNewswire February 27, 2025

Podcasts